Iovance Biotherapeutics Investor Presentation — February 2021

Document content

Tumor Infiltrating Lymphocyte Cell

Therapy for Treatment of Solid Tumors

© 2021, Iovance Biotherapeutics, Inc 1Forward Looking Statements

2Certain matters discussed in this presentation are “forward-looking statements” of Iovance Biotherapeutics, Inc, Inc. (hereinafter referred to a s the “Company,” “we,”

“us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). All such written or oral statements made in th is presentation,

other than statements of historical fact, are forward-looking statements and are intended to be covered by the safe harbor for forward-looking state ments provided by

the PSLRA. Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “ anticipates,”

“expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertai nty of future events or

outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in lig ht of

management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be ap propriate. Forward-

looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, w hether as

a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risk s, uncertainties

and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements and develop ments to be

materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, de velopments and

business decisions to differ materially from forward-looking statements are described in the sections titled “Risk Factors“ in our filings with the Securities and

Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the f ollowing

substantial known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19 pandemic; risks related to the timing of a nd our ability to

successfully develop, submit, obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other act i o nw i t hr e s p e c tt o ,

our product candidates, and our ability to successfully commercialize any product candidates for which we obtain FDA approval; preliminary and inte rim clinical